Dog Cancer Collaboration


 

TIDMHML 
 
RNS Number : 5891L 
Henderson Morley PLC 
14 January 2009 
 
14 January 2009 
 
 
HENDERSON MORLEY PLC 
(AIM: HML) 
("Henderson Morley" or "the Company") 
 
DOG CANCER COLLABORATION 
 
Henderson Morley is pleased to announce the start of a Collaborative Research 
Programme with a US based centre of excellence for companion animal cancer. The 
centre is the largest research unit for animal cancers in the US, and the 
collaboration is to develop treatments for two different forms of dog cancer. 
 
For the first time, the studies will explore the use of PREPS and L-particles as 
a treatment for cancer. The study will involve dogs that already have cancer, 
and their existing treatment has either failed or is likely to prove 
ineffective. 
 
PREPS and L-particles have been engineered to express proteins that are only 
found in tumours, or are over produced by certain cancers. In affected animals, 
these proteins are not recognised by the immune system as being foreign, and 
therefore the tumours are able to grow. PREPS and L-particles present these 
engineered proteins to the immune system so that an immune response is expected 
to be generated against them, mobilising the animals' immune system against the 
tumours. 
 
The market for dog cancer treatments is significant and growing, as dogs are 
living longer, and pet ownership is increasing. There are 74 million dogs owned 
in the US, with 4 million new dog cancer diagnoses being made every year. We 
believe that the numbers in the EU are similar. The first two cancers under 
investigation are two of the most common forms of dog cancer with a large 
potential market. 
 
The data generated in these studies will also be extremely useful in support of 
the on-going licensing efforts for the use of PREPS and L-particles as 
treatments for human cancer. 
 
Ethics committee approval for the first of these two studies has been granted, 
and the second is expected to be approved within a few weeks. It is expected to 
start recruiting patients in March-April with approximately 10 animals involved 
in each study. The time taken to gain marketing approval for companion animal 
cancer products is significantly shorter than the human equivalent. 
 
The Company is already in discussions with major animal health companies to seek 
development agreements or an out-licence of the companion cancer applications of 
PREPS and L-particles. 
 
Executive Chairman Andrew Knight said "This is an important potential commercial 
application for the PREPS and L-particles vaccine platform and we are pleased to 
be working with the Centre of Excellence in this respect. The companion animal 
market is clearly a growing opportunity for Henderson Morley." 
 
=--ENDS--- 
 
 
 
ENQUIRIES: 
 
HENDERSON MORLEY PLC                                                     0121 
442 4600 
Andrew Knight, Chairman 
 
BISHOPSGATE COMMUNICATIONS LTD 0207 562 3350 
Maxine Barnes 
 Nick Rome 
 
BREWIN DOLPHIN INVESTMENT BANKING                           0113 241 0126 
Neil Baldwin 
 
HYBRIDAN LLP   0203 159 5085 
Claire Noyce/Stephen Austin 
 
Further information on Henderson Morley plc can be accessed through the 
Company's website at www.henderson-morley.com 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 RESILFEDLIIVLIA

Henderson Mrly. (LSE:HML)
過去株価チャート
から 6 2024 まで 7 2024